TERAPIJA BOLA SENZOMOTORNE POLINEUROPATIJE U INFEKCIJI IZAZVANOJ COVID-19 VIRUSOM
Sažetak
Sedamdesettrogodišnji muškarac oboleo je od SARS-CoV-2 sa blagom kliničkom slikom. Desetog dana bolesti javljaju se simetrična distribucija spontanog bola i dizestezija u oba stopala. Inicijalna terapija bola, ordinirana od strane primarne zdravstvene zaštite, nije dala zadovoljavajući efekat. Nova terapija, ordinirana od strane specijaliste medicine bola, podrazumevala je kombinaciju antikonvulziva, antidepresiva i adjuvantne terapije. Time je izvršena delimična, ali ipak zadovoljavajuća redukcija bola. Edukacija/reedukacija službe primarne zdravstvene zaštite u pravcu terapije bola ubrzala bi detekciju i simptomatsko lečenje u ranim fazama infekcije izazvane COVID-19 virusom. Još bolji predlog podrazumevao bi upućivanje ovih bolesnika specijalistima terapije bola.
Reference
Abdelnour L, Eltahir Abdalla M, Babiker S. COVID 19 infection presenting as motor peripheral neuropathy. J Formos Med Assoc 2020;119(6):1119-20. [CrossRef][PubMed]
Binder A, Baron R. The Pharmacological Therapy of Chronic Neuropathic Pain. Dtsch Arztebl Int 2016;113(37):616-25. [CrossRef][PubMed]
Bureau BL, Obeidat A, Dhariwal MS, Jha P. Peripheral Neuropathy as a Complication of SARS-Cov-2. Cureus 2020;12(11):e11452. [CrossRef][PubMed]
Córdova-Martínez A, Caballero-García A, Pérez-Valdecantos D, Roche E, Noriega-González DC. Peripheral Neuropathies Derived from COVID-19: New Perspectives for Treatment. Biomedicines 2022;10(5):1051. [CrossRef][PubMed]
Córdova-Martínez A, Caballero-García A, Pérez-Valdecantos D, Roche E, Noriega-González DC. Peripheral Neuropathies Derived from COVID-19: New Perspectives for Treatment. Biomedicines. 2022;10(5):1051.
Correia AO, Feitosa PWG, Moreira JLS, Nogueira SÁR, Fonseca RB, Nobre MEP. Neurological manifestations of COVID-19 and other coronaviruses: A systematic review. Neurol Psychiatry Brain Res 2020;37:27-32. [CrossRef][PubMed]
Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 2020;368(6497):1331-5. [CrossRef][PubMed]
Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368(6497):1331-1335.
Dragomanova S, Miteva S, Nicoletti F, Mangano K, Fagone P, Pricoco S, et al. Therapeutic Potential of Alpha-Lipoic Acid in Viral Infections, including COVID-19. Antioxidants (Basel) 2021;10(8):1294. [CrossRef][PubMed]
Drożdżal S, Rosik J, Lechowicz K, Machaj F, Szostak B, Majewski P, et al. COVID-19: Pain Management in Patients with SARS-CoV-2 Infection-Molecular Mechanisms, Challenges, and Perspectives. Brain Sci 2020;10(7):465. [CrossRef][PubMed]
Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14(2):162-73. [CrossRef][PubMed]
Garg RK. Spectrum of Neurological Manifestations in Covid-19: A Review. Neurol India 2020;68(3):560-72. [CrossRef][PubMed]
Lai CC, Ko WC, Lee PI, Jean SS, Hsueh PR. Extra-respiratory manifestations of COVID-19. Int J Antimicrob Agents 2020;56(2):106024. [CrossRef][PubMed]
Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev 2009;(4):CD007115. [CrossRef][PubMed]
Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020;77(6):683-90. [CrossRef][PubMed]
Rifino N, Censori B, Agazzi E, Alimonti D, Bonito V, Camera G, et al. Neurologic manifestations in 1760 COVID-19 patients admitted to Papa Giovanni XXIII Hospital, Bergamo, Italy. J Neurol 2021;268(7):2331-8. [CrossRef][PubMed]
Suh J, Mukerji SS, Collens SI, Padera RF Jr, Pinkus GS, Amato AA, et al. Skeletal Muscle and Peripheral Nerve Histopathology in COVID-19. Neurology 2021;97(8):e849-e858. [CrossRef][PubMed]
Vo T, Rice ASC, Dworkin RH. Non‐steroidal anti‐inflammatory drugs for neuropathic pain: How do we explain continued widespread use?. Pain 2009;143(3):169‐71. [CrossRef][PubMed]
Yachou Y, El Idrissi A, Belapasov V, Ait Benali S. Neuroinvasion, neurotropic, and neuroinflammatory events of SARS-CoV-2: understanding the neurological manifestations in COVID-19 patients. Neurol Sci 2020;41(10):2657-69. [CrossRef][PubMed]